Please use this identifier to cite or link to this item: http://cmuir.cmu.ac.th/jspui/handle/6653943832/54686
Full metadata record
DC FieldValueLanguage
dc.contributor.authorGeorges Juvelekianen_US
dc.contributor.authorWaleed El-Sorougien_US
dc.contributor.authorChaicharn Pothiraten_US
dc.contributor.authorFaisal Yunusen_US
dc.contributor.authorTeresita De Guiaen_US
dc.contributor.authorHan Pin Kuoen_US
dc.contributor.authorShalma Basu Patnaiken_US
dc.contributor.authorVirginia Pilipovicen_US
dc.date.accessioned2018-09-04T10:20:47Z-
dc.date.available2018-09-04T10:20:47Z-
dc.date.issued2015-10-05en_US
dc.identifier.issn11782005en_US
dc.identifier.issn11769106en_US
dc.identifier.other2-s2.0-84943607194en_US
dc.identifier.other10.2147/COPD.S83071en_US
dc.identifier.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84943607194&origin=inwarden_US
dc.identifier.urihttp://cmuir.cmu.ac.th/jspui/handle/6653943832/54686-
dc.description.abstract© 2015 Juvelekian et al. Aim: INFLOW (INdacaterol eFfectiveness and utiLizatiOn in COPD: real World evaluation) was a prospective, noninterventional study assessing the effectiveness and safety of long-acting bronchodilators in patients with chronic obstructive pulmonary disease (COPD) from the Middle East, Asia, and South Africa. Methods: Patients newly prescribed or switched to indacaterol or other long-acting β2-agonist (LABA), or tiotropium (monotherapy or in combination) were evaluated over 6 months. The primary endpoint was the clinical COPD questionnaire overall score at the end of the study. Results: Data were analyzed from 1,710 patients (mean postbronchodilator forced expiratory volume in 1 second, 59% predicted) who received indacaterol (n=1,179), other LABA (n=68), tiotropium (n=271), indacaterol plus tiotropium (n=167), or other LABA plus tiotropium (n=25). Across treatments, clinical COPD questionnaire overall score improved from baseline by 0.81–1.26 points (all P,0.0001), 63%–84% of patients were satisfied/very satisfied, and physicians rated effectiveness as good/very good in 63%–80% of cases. The indacaterol inhaler was rated easy/very easy to use by the majority of patients, and physicians considered its use clearly understood by most patients. All treatments had acceptable tolerability. Conclusion: In real life clinical practice across a diverse region, indacaterol and other long-acting bronchodilators improved health status and were well regarded by patients and physicians.en_US
dc.subjectMedicineen_US
dc.titleAreal-world evaluation of indacaterol and other bronchodilators in COPD: The INFLOW studyen_US
dc.typeJournalen_US
article.title.sourcetitleInternational Journal of COPDen_US
article.volume10en_US
article.stream.affiliationsSaint George Hospital University Medical Centeren_US
article.stream.affiliationsHelwan Universityen_US
article.stream.affiliationsChiang Mai Universityen_US
article.stream.affiliationsUniversitas Indonesiaen_US
article.stream.affiliationsPhilippine Heart Centeren_US
article.stream.affiliationsChang Gung Memorial Hospitalen_US
article.stream.affiliationsNovartis Healthcare Pvt. Ltd.en_US
article.stream.affiliationsNovartis International AGen_US
Appears in Collections:CMUL: Journal Articles

Files in This Item:
There are no files associated with this item.


Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.